Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi

Vaccine

Volumn 30, Issue 5, 2012, Pages 853-861

  Micoli, F ^a   Rondini, S ^a   Pisoni, I ^a   Giannelli, C ^a   Di Cioccio, V ^a   Costantino, P ^a   Saul, A ^a   Martin, L B ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Conjugate vaccine; Salmonella Typhi; Vi polysaccharide; ViCRM 197

Indexed keywords

ALCOHOL; BACTERIAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDE VI DIPHTHERIA TOXOID CRM197 CONJUGATE VACCINE; CETRIMIDE; DIPHTHERIA TOXOID CRM197; HYDRAZIDE; IMIDE; SALMONELLOSIS VACCINE; SODIUM ION; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BACTERIUM CULTURE; CITROBACTER; DERIVATIZATION; DRUG CONJUGATION; DRUG QUALITY; GEL PERMEATION CHROMATOGRAPHY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; PURIFICATION; SOLUBILIZATION; SUPERNATANT; VACCINE PRODUCTION;

BACTERIAL PROTEINS; CITROBACTER; HUMANS; POLYSACCHARIDES, BACTERIAL; TECHNOLOGY, PHARMACEUTICAL; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE;

EID: 84855453738     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.108     Document Type: Article

References (31)

1. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010, 50(January (2)):241-246.
2. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B. Typhoid fever in children aged less than 5 years. Lancet 1999, 354(August (9180)):734-737.
3. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11(February (2)):326-329.
4. Siddiqui F.J., Rabbani F., Hasan R., Nizami S.Q., Bhutta Z.A. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis 2006, 10(May (3)):215-222.
5. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996, 14(April (5)):435-438.
6. Klugman K.P., Gilbertson I.T., Koornhof H.J., Robbins J.B., Schneerson R., Schulz D. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, 2(November (8569)):1165-1169.
7. Fraser A., Goldberg E., Acosta C.J., Paul M., Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007, (3):CD001261.
8. Kossaczka Z. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999.
9. Kossaczka Z., Bystricky S., Bryla D.A., Shiloach J., Robbins J.B., Szu S.C. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun 1997, 65(Jun (6)):2088-2093.
10. Canh D.G., Lin F.Y., Thiem V.D., Trach D.D., Trong N.D., Mao N.D. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004, 72(November (11)):6586-6588.
11. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(April (17)):1263-1269.
12. Thiem V.D., Lin F.Y., Canh D.G., Son N.H., Anh D.D., Mao N.D. Vi conjugate typhoid vaccine (VirEPA) is safe, elicits protective levels of IgG anti-Vi and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011 March, 18:730-735.
13. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., Clemens J.D. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar Typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17(January (1)):73-79.
14. An S.J., Yoon Y.K., Kothari S., Kothari N., Kim J.A., Lee E. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 2011, 29(October (44)):7618-7623.
15. Shah N.K. Indian conjugate Vi typhoid vaccine: do we have enough evidence?. Indian Pediatr 2009, 46(February (2)):181-182.
16. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984, 12(May (10)):4063-4069.
17. Micoli F., Rondini S., Pisoni I., Proietti D., Berti F., Costantino P. ViCRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011, 29(January (4)):712-720.
18. Rondini S., Micoli F., Lanzilao L., Hale C., Saul A.J., Martin L.B. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii ViCRM197 conjugate as a vaccine for Salmonella enterica Serovar Typhi. Clin Vaccine Immunol 2011, 18(March (3)):460-468.
19. Daniels E.M., Schneerson R., Egan W.M., Szu S.C., Robbins J.B. Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect Immun 1989, 57(October (10)):3159-3164.
20. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180(August (1)):249-261.
21. Lemercinier X., Martinez-Cabrera I., Jones C. Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine. Biologicals 2000, 28(March (1)):17-24.
22. Nohta H., Sonoda J., Yoshida H., Satozono H., Ishida J., Yamaguchi M. Liquid chromatographic determination of dicarboxylic acids based on intramolecular excimer-forming fluorescence derivatization. J Chromatogr A 2003, 1010(August (1)):37-44.
23. WHO. Requirements for Vi polysaccharide typhoid vaccine. Geneva; 1994 [Report No.: 840].
24. Szu S.C., Li X.R., Stone A.L., Robbins J.B. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun 1991, 59(December (12)):4555-4561.
25. Szu S.C., Bystricky S., Hinojosa-Ahumada M., Egan W., Robbins J.B. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1→4)-alpha-d-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect Immun 1994, 62(December (12)):5545-5549.
26. Broker M., Costantino P., DeTora L., McIntosh E.D., Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011, 39(July (4)):195-204.
27. Shinefield H.R. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine 2010, 28(June (27)):4335-4339.
28. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18(September (9)):757-763.
29. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299(January (2)):173-184.
30. Knuf M., Kowalzik F., Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011, 29(July (31)):4881-4890.
31. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., De Coster I., et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 2011; 2011, 6(9):e25398.